Real Time Touch



new TOP 200 Companies filing patents this week

new Companies with the Most Patent Filings (2010+)




Real Time Touch

Celgene Corporation patents


Recent patent applications related to Celgene Corporation. Celgene Corporation is listed as an Agent/Assignee. Note: Celgene Corporation may have other listings under different names/spellings. We're not affiliated with Celgene Corporation, we're just tracking patents.

ARCHIVE: New 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 | Company Directory "C" | Celgene Corporation-related inventors


Modified t lymphocytes having improved specificity

. . Provided herein are modified t lymphocytes comprising chimeric receptors and methods of use thereof.. . ... Celgene Corporation

Bromodomain inhibitors

The present invention relates to substituted heterocyclic derivative compounds, compositions comprising said compounds, and the use of said compounds and compositions for epigenetic regulation by inhibition of bromodomain-mediated recognition of acetyl lysine regions of proteins, such as histones. Said compositions and methods are useful for the treatment of cancer and neoplastic disease.. ... Celgene Corporation

Histone demethylase inhibitors

The present invention relates generally to compositions and methods for treating cancer and neoplastic disease. Provided herein are substituted pyrrolopyridine derivative compounds and pharmaceutical compositions comprising said compounds. ... Celgene Corporation

Use of biomarkers for predicting clinical sensitivity to cancer treatment

A method of identifying a subject having cancer who is likely to be responsive to a treatment compound, comprising administering the treatment compound to a subject having cancer; obtaining a sample from the subject; determining the level of a biomarker in the sample from the subject; and diagnosing the subject as being likely to be responsive to the treatment compound if the level of the biomarker in the sample of the subject changes as compared to a reference level of the biomarker; wherein the treatment compound is a compound of formula (i):. . ... Celgene Corporation

Inhibitors of lysine specific demethylase-1

The present invention relates generally to compositions and methods for treating cancer and neoplastic disease. Provided herein are substituted heterocyclic derivative compounds and pharmaceutical compositions comprising said compounds. ... Celgene Corporation

Methods using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for treatment of mantle cell lymphomas

Methods of treating, preventing or managing mantle cell lymphomas are disclosed. The methods encompass the administration of an immunomodulatory compound of the invention known as revlimid® or lenalidomide. ... Celgene Corporation

Histone demethylase inhibitors

The present disclosure relates generally to compositions and methods for treating cancer and neoplastic disease. Provided herein are substituted pyridine derivative compounds and pharmaceutical compositions comprising said compounds. ... Celgene Corporation

Methods for treating hematological cancer and the use of biomarkers as a predictor for responsiveness to treatment compounds

A method for predicting the responsiveness of a patient having a hematological cancer to a treatment compound, comprising obtaining a biological sample from the patient having the hematological cancer; determining the expression level of one, two, three, four, five, or more genes; and comparing the expression level of the one, two, three, four, five, or more genes in the biological sample with a reference expression level of the same genes, wherein the treatment compound is 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione (lenalidomide), 3-(5-amino-2-methyl-4-oxo-4h-quinazolin-3-yl)-piperidine-2,6-dione (compound a), or a stereoisomer, pharmaceutically acceptable salt, solvate, hydrate, co-crystal, clathrate, or a polymorph thereof.. . ... Celgene Corporation

Methods for treating solid tumors and the use of biomarkers as a predictor of clinical sensitivity to immunomodulatory therapies

A method of identifying a subject having a solid tumor who is likely to be responsive to a treatment compound, comprising: administering the treatment compound to a subject having the solid tumor; obtaining a sample from the subject; determining the level of a biomarker in the sample from the subject, and diagnosing the subject as being likely to be responsive to the treatment compound if the level of the biomarker in the sample of the subject changes as compared to a reference level of the biomarker.. . ... Celgene Corporation

Methods for measuring small molecule affinity to cereblon

A complex comprises a crbn having a europium-anti-his antibody on the n-terminus of the crbn, and a cy5-conjugated small molecule, wherein the cy5-conjugated small molecule binds the crbn, and uses thereof for identifying therapeutic compounds.. . ... Celgene Corporation

Antiproliferative compounds and methods of use thereof

Compounds of formula i for treating, preventing or managing cancer are disclosed. Also disclosed are methods of treating, preventing or managing cancer, such as leukemia, comprising administering the compounds. ... Celgene Corporation

Methods of synthesis of (1r,2r,5r)-5-amino-2-methylcyclohexanol hydrochloride and intermediates useful therein

Provided herein are methods and intermediates for making (1r,2r,5r)-5-amino-2-methylcyclohexanol hydrochloride, which are useful for the preparation of compounds useful for the treatment of a disease, disorder, or condition associated with the jnk pathway.. . ... Celgene Corporation

Methods for determining drug efficacy using cereblon-associated proteins

Use of cereblon-associated proteins as biomarkers for clinical sensitivity to cancer, inflammatory diseases, and patient response to drug treatment.. . ... Celgene Corporation

Methods of treating myelodysplastic syndromes with a combination therapy using lenalidomide and azacitidine

Methods of treating, preventing and/or managing myelodysplastic syndromes are disclosed. Specific methods encompass the administrations of 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidin-2,6-dione in combination with 5-azacytidine.. ... Celgene Corporation

07/19/18 / #20180200255

Salts and solid forms of (s)-3-(4-((4-(morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione and compositions comprising and methods of using the same

Salts and solid forms of 3-(4-((4-(morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione, or a stereoisomer thereof, are disclosed. Compositions comprising and methods of using the salts and solid forms are also disclosed.. ... Celgene Corporation

07/19/18 / #20180200245

Solid forms comprising 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione and a coformer, compositions and methods of use thereof

Provided herein are solid forms comprising (a) 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione and (b) a coformer. Pharmaceutical compositions comprising the solid forms (e.g., cocrystals) and methods for treating, preventing and managing various disorders are also disclosed.. ... Celgene Corporation

07/12/18 / #20180193342

Combination therapy for treatment of hematological cancers and solid tumors

Provided herein are methods for treating, preventing, and/or managing hematological cancers and solid tumors using combination therapy of 3-(5-amino-2-4-oxo-4h-quinazolin-3-yl)-piperidine-2,6-dione and checkpoint inhibitors.. . ... Celgene Corporation

07/05/18 / #20180186767

Antiproliferative compounds, and their pharmaceutical compositions and uses

Compounds of formula a-i and b-i, compositions comprising the compounds, methods of making the compounds and methods of their uses are disclosed.. . ... Celgene Corporation

06/28/18 / #20180179204

Inhibitors of lysine specific demethylase-1

The present invention relates generally to compositions and methods for treating cancer and neoplastic disease. Provided herein are substituted heterocyclic derivative compounds and pharmaceutical compositions comprising said compounds. ... Celgene Corporation

06/14/18 / #20180162857

Histone demethylase inhibitors

The present invention relates generally to compositions and methods for treating cancer and neoplastic disease. Provided herein are substituted pyrido[3,4-d]pyrimidin-4-one derivative compounds and pharmaceutical compositions comprising said compounds. ... Celgene Corporation

06/14/18 / #20180161426

In vitro cell culture methods for beta-thalassemia using activin type ii receptor ligand traps

Provided herein are methods of treating beta-thalassemia in a subject comprising administering to the subject an activin type ii receptor (actrii) signaling inhibitor (e.g., an activin ligand trap) and utilizing one or more in vitro cell culture methods provided herein in (i) selection of the subject to be treated according to the methods provided herein; and/or (ii) monitoring of the subject being treated according to the methods provided herein.. . ... Celgene Corporation

06/07/18 / #20180155316

4'-o-substituted isoindoline derivatives and compositions comprising and methods of using the same

Provided are 4′-o substituted isoindoline compounds, and pharmaceutically acceptable salts, solvates, clathrates, stereoisomers, and prodrugs thereof. Methods of use, and pharmaceutical compositions of these compounds are disclosed.. ... Celgene Corporation

06/07/18 / #20180153916

Isotopologues of 5-azacytidine

The present disclosure provides pharmaceutical compositions comprising cytidine analogs for oral administration, wherein the compositions release the cytidine analog substantially in the stomach. Also provided are methods of treating diseases and disorders using the oral formulations provided herein.. ... Celgene Corporation

05/17/18 / #20180134710

Bromodomain inhibitors

The present invention relates to substituted heterocyclic derivative compounds, compositions comprising said compounds, and the use of said compounds and compositions for epigenetic regulation by inhibition of bromodomain-mediated recognition of acetyl lysine regions of proteins, such as histones. Said compositions and methods are useful for the treatment of cancer and neoplastic disease.. ... Celgene Corporation

05/10/18 / #20180127408

Inhibitors of lysine specific demethylase-1

The present invention relates generally to compositions and methods for treating cancer and neoplastic disease. Provided herein are substituted heterocyclic derivative compounds and pharmaceutical compositions comprising said compounds. ... Celgene Corporation

05/10/18 / #20180125844

Treatment of relapsed and/or refractory solid tumors and non-hodgkin's lymphomas

Methods are provided for the treatment of relapsed and/or refractory solid tumors (including neuroendocrine carcinomas (nec)) and non-hodgkin's lymphomas (nhls) and the like, using substituted heterocyclic derivative compounds and pharmaceutical compositions comprising compounds useful for the inhibition of lysine specific demethylase-1 (lsd-1).. . ... Celgene Corporation

05/03/18 / #20180122497

Systems, methods and data structures for efficient processing and presentation of patient medical data

Systems, methods and data structures for transforming patient data from source computer data structures into another format of a different computer data structure for efficient processing and visualization of patient data for medical treatment, e.g., a clinical trial, are described. Source data of various source data structures for the patients is selected, where the source data is arranged among data fields, each of which has a data type and a content type. ... Celgene Corporation

05/03/18 / #20180118720

Histone demethylase inhibitors

The present invention relates generally to compositions and methods for treating cancer and neoplastic diseases. Provided herein are substituted imidazole-pyridine derivative compounds and pharmaceutical compositions comprising said compounds. ... Celgene Corporation

05/03/18 / #20180118713

6-, 7-, or 8-substituted quinazolinone derivatives and compositions comprising and methods of using the same

Provided are quinazolinone compounds, and pharmaceutically acceptable salts, solvates, clathrates, stereoisomers, and prodrugs thereof. Methods of use, and pharmaceutical compositions of these compounds are disclosed.. ... Celgene Corporation

05/03/18 / #20180117030

Bromodomain and extra-terminal protein inhibitor combination therapy

The present disclosure relates generally to compositions and methods of treating neoplastic diseases or cancers, such as glioblastoma and non-hodgkin's lymphomas, or other cancers in which the subject suffers from an advanced solid tumor, comprising a combination of, or administering a combination of, a bromodomain and extra-terminal protein (bet) inhibitor and at least one chemotherapeutic agent, which does not inhibit bet directly. The bet inhibitor/chemotherapeutic agent combination, or combination therapy, can yield synergistic effects, thereby increasing the effectiveness of the cancer treatment as compared with the administration of either the bet inhibitor or the chemotherapeutic agent alone.. ... Celgene Corporation

04/19/18 / #20180105521

Histone demethylase inhibitors

The present invention relates generally to compositions and methods for treating cancer and neoplastic disease. Provided herein are substituted pyrrolopyridine derivative compounds and pharmaceutical compositions comprising said compounds. ... Celgene Corporation

04/05/18 / #20180094057

Methods of treating vitiligo using pd-1 binding proteins

Provided herein are methods for managing, treating, or preventing vitiligo using proteins that specifically bind to programmed death-1 (pd-1) and modulate the expression and/or activity of pd-1.. . ... Celgene Corporation

04/05/18 / #20180093965

Isotopologues of 3-(5-amino-2-methyl-4-oxoquinazolin-3(4h)-yl)piperidine-2,6-dione and methods of preparation thereof

Provided herein are deuterated isotopologues of 3-(5-amino-2-methyl-4-oxoquinazolin-3(4h)-yl)piperidine-2,6-dione, or enantiomers or mixtures of enantiomers thereof; or a pharmaceutically acceptable salt, solvate, cocrystal or polymorph thereof, and processes for making the same. Pharmaceutical compositions comprising the isotopes-enriched compounds, and methods of using such compounds are also provided.. ... Celgene Corporation

04/05/18 / #20180092975

Methods of treating immune disorders using pd-1 binding proteins

Provided herein are methods for managing, treating, or preventing immune disorders, such as autoimmune diseases, using proteins that specifically bind to programmed death-1 (pd-1) and modulate the expression and/or activity of pd-1.. . ... Celgene Corporation

03/15/18 / #20180072700

Polymorphic forms of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione

Polymorphic forms of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione are disclosed. Compositions comprising the polymorphic forms, methods of making the polymorphic forms and methods of their use are also disclosed.. ... Celgene Corporation

03/15/18 / #20180072687

Heteroaryl compounds and uses thereof

The present invention provides compounds, pharmaceutically acceptable compositions thereof, and methods of using the same.. . ... Celgene Corporation

03/01/18 / #20180055844

Methods of treating cancer using 3-(5-amino-2-methyl-4-oxo-4h-quinazolin-3-yl)-piperidine-2,6-dione

Provided herein are methods of treating, preventing and/or managing cancers, which comprise administering to a patient 3-(5-amino-2-methyl-4-oxo-4h-quinazolin-3-yl)-piperidine-2,6-dione, or an enantiomer or a mixture of enantiomers thereof, or a pharmaceutically acceptable salt, solvate, hydrate, co-crystal, clathrate, or polymorph thereof.. . ... Celgene Corporation

02/15/18 / #20180044334

Histone demethylase inhibitors

The present disclosure relates generally to compositions and methods for treating cancer and neoplastic disease. Provided herein are substituted pyridine derivative compounds and pharmaceutical compositions comprising said compounds. ... Celgene Corporation

02/15/18 / #20180044320

Compositions comprising an inhibitor of lysine specific demethylase-1

Described herein are amorphous and crystalline forms of pharmaceutically acceptable salts of the lysine specific demethylase-1 inhibitor 4-[2-(4-aminopiperidin-1-yl)-5-(3-fluoro-4-methoxy-phenyl)-1-methyl-6-oxo-1,6-dihydropyrimidin-4-yl]-2-fluorobenzonitrile. Also described are pharmaceutical compositions suitable for administration to a mammal that include the lysine specific demethylase-1 inhibitor, and methods of using the lysine specific demethylase-1 inhibitor for treating diseases or conditions that are associated with lysine specific demethylase-1 activity.. ... Celgene Corporation

02/15/18 / #20180044318

Processes for the preparation of 4-amino-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione compounds

The present invention provides new processes for the preparation of unsubstituted and substituted 4-amino-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione compounds which are useful, for example, for preventing or treating diseases or conditions related to an abnormally high level or activity of tnf-α. The invention can provide improved and/or efficient processes for the commercial production of unsubstituted and substituted 4-amino-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione compounds, including, but not limited to, unsubstituted 4-amino-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione.. ... Celgene Corporation

02/15/18 / #20180044296

Histone demethylase inhibitors

The present invention relates generally to compositions and methods for treating cancer and neoplastic disease. Provided herein are substituted amidopyridine or amidopyridazine derivative compounds and pharmaceutical compositions comprising said compounds. ... Celgene Corporation

02/15/18 / #20180042930

Methods of treatment of malignancies

Provided are methods and compositions for treating a malignancy in patients carrying an idh2 mutation.. . ... Celgene Corporation

02/15/18 / #20180042914

Bromodomain inhibitor

Described herein is the bromodomain inhibitor 4-[2-(cyclopropylmethoxy)-5-methylsulfonylphenyl]-2-methylisoquinolin-1-one, including crystalline forms, amorphous forms, solvates, and hydrates thereof, as well as pharmaceutical compositions that include this bromodomain inhibitor. In some embodiments, the pharmaceutical composition comprises 4-[2-(cyclopropylmethoxy)-5-methylsulfonylphenyl]-2-methylisoquinolin-1-one that has been processed by micronization or spray dried dispersion. ... Celgene Corporation

02/08/18 / #20180037567

Arylmethoxy isoindoline derivatives and compositions comprising and methods of using the same

Provided are 4′-arylmethoxy isoindoline compounds, and pharmaceutically acceptable salts, solvates, clathrates, stereoisomers, and prodrugs thereof. Methods of use, and pharmaceutical compositions of these compounds are disclosed.. ... Celgene Corporation

02/01/18 / #20180028552

Combination therapy for treating cancer

The present disclosure relates to a combination of an inhibitor of human histone methyltransferase dot1l, such as epz-5676 or salts thereof, and one or more dnmt inhibitors, and methods of combination therapy for administering to subjects in need thereof for the treatment of cancer.. . ... Celgene Corporation

02/01/18 / #20180028508

Inhibitors of lysine specific demethylase-1

The present invention relates generally to compositions and methods for treating cancer and neoplastic disease. Provided herein are substituted heterocyclic derivative compounds and pharmaceutical compositions comprising said compounds. ... Celgene Corporation

01/25/18 / #20180021325

Antiproliferative compounds and methods of use thereof

. . Compounds of formula i for treating, preventing or managing cancer are disclosed. Also disclosed are methods of treating, preventing or managing cancer, such as leukemia, comprising administering the compounds. ... Celgene Corporation

01/04/18 / #20180000808

Solid forms comprising 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione and a coformer, compositions and methods of use thereof

Provided herein are solid forms comprising (a) 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione (lenalidomide) and (b) a coformer. Pharmaceutical compositions comprising the solid forms and methods for treating, preventing and managing various disorders are also disclosed.. ... Celgene Corporation

12/28/17 / #20170369572

Anti-cd47 antibodies and uses thereof

Provided herein are compositions, methods and uses involving antibodies that specifically bind to human cd47. Also provided are uses and methods, such as therapeutic methods, diagnostic methods, and methods of making such antibodies.. ... Celgene Corporation

12/28/17 / #20170369471

5-substituted quinazolinone derivatives and compositions comprising and methods of using the same

Provided are 5-substituted quinazolinone compounds, for example, of formula (i), and pharmaceutically acceptable salts, solvates, clathrates, stereoisomers, and prodrugs thereof. Methods of use for treating angiogenesis or cytokine related disorders, and pharmaceutical compositions of these compounds are disclosed.. ... Celgene Corporation

12/21/17 / #20170362660

Cereblon isoforms and their use as biomarkers for therapeutic treatment

Provided herein are cereblon isoforms and methods of their use as biomarkers for treating a disease, disorder, or condition with a treatment compound, e.g., thalidomide, lenalidomide, pomalidomide, 3-(5-amino-2-methyl-4-oxoquinazolin-3 (4h)-yl)-piperidine-2,6-dione, or (s)-3-(4-((4-(morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione.. . ... Celgene Corporation

12/21/17 / #20170362240

4,6-substituted-pyrazolo[1,5-a]pyrazines as janus kinase inhibitors

Compounds of formula i: and stereoisomers and pharmaceutically acceptable salts and solvates thereof in which r1, r2, r3 and r4 have the meanings given in the specification, are inhibitors of one or more jak kinases and are useful in the treatment of jak kinase-associated diseases and disorders, such as autoimmune diseases, inflammatory diseases, rejection of transplanted organs, tissues and cells, as well as hematologic disorders and malignancies and their co-morbidities.. . ... Celgene Corporation

12/21/17 / #20170360952

Biomolecule conjugates

The present invention relates to biomolecule conjugates which comprise a biomolecule wherein at least one non-natural amino acid (nnaa) is integral to the structure of the biomolecule and wherein the nnaa is a point of attachment of a linker to which a payload, particularly a cytotoxic agent, is attached. More specifically, this invention relates to conjugates of cell-binding agents and active release products comprising cytotoxic agents wherein the conjugates are produced by means of a cycloaddition reaction. ... Celgene Corporation

12/07/17 / #20170349556

Inhibitors of lysine specific demethylase-1

. . . . The present invention relates generally to compositions and methods for treating cancer and neoplastic disease. Provided herein are substituted heterocyclic derivative compounds and pharmaceutical compositions comprising said compounds. ... Celgene Corporation

12/07/17 / #20170349555

Inhibitors of lysine specific demethylase-1

The present invention relates generally to compositions and methods for treating cancer and neoplastic disease. Provided herein are substituted heterocyclic derivative compounds and pharmaceutical compositions comprising said compounds. ... Celgene Corporation

12/07/17 / #20170348298

Treatment of a hematologic malignancy with 2-(4-chlorophenyl)-n-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-2,2-difluoroacetamide

Provided herein are methods of treating, preventing, managing, and/or ameliorating leukemia or myelodysplastic syndrome comprising administering 2-(4-chlorophenyl)-n-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-2,2-difluoroacetamide or a stereoisomer or mixture of stereoisomers, an isotopologue, pharmaceutically acceptable salt, tautomer, solvate, hydrate, co-crystal, clathrate, or polymorph thereof to a patient.. . ... Celgene Corporation

12/07/17 / #20170348284

Use of marizomib for the treatment of central nervous system (cns) cancers

The present disclosure relates to treatment of central nervous system (cns) cancers (e.g., malignant glioma, glioblastoma, or cns-multiple myeloma) using marizomib. The disclosure further relates to uses of synergistic combinations of marizomib with additional therapeutic agents such as bevacizumab, daratumumab, temozolomide, pomalidomide, and radiotherapy.. ... Celgene Corporation

11/30/17 / #20170342050

Solid forms of 3-(5-amino-2-methyl-4-oxo-4h-quinazolin-3-yl)-piperidine-2,6-dione, and their pharmaceutical compositions and uses

Solid forms comprising 3-(5-amino-2-methyl-4-oxo-4h-quinazolin-3-yl)-piperidine-2,6-dione, compositions comprising the solid forms, methods of making the solid forms and methods of their uses are disclosed. . ... Celgene Corporation

11/23/17 / #20170334879

Histone demethylase inhibitors

The present invention relates generally to compositions and methods for treating cancer and neoplastic diseases. Provided herein are substituted imidazole-pyridine derivative compounds and pharmaceutical compositions comprising said compounds. ... Celgene Corporation

11/16/17 / #20170326234

Combination therapies

The present invention provides combination therapy methods of treating a proliferative disease (such as cancer) comprising a first therapy comprising administering to an individual an effective amount of a taxane in a nanoparticle composition, and a second therapy which may include the administration of an effective amount of at least one other agent that antagonizes a pd-1 pathway in a cell.. . ... Celgene Corporation

11/16/17 / #20170326116

Histone demethylase inhibitors

The present invention relates generally to compositions and methods for treating cancer and neoplastic disease. Provided herein are substituted pyrrolopyridine derivative compounds and pharmaceutical compositions comprising said compounds. ... Celgene Corporation

11/09/17 / #20170320839

Selective sphingosine 1 phosphate receptor modulators and methods of chiral synthesis

Compounds that selectively modulate the sphingosine 1 phosphate receptor are provided including compounds which modulate subtype 1 of the s1p receptor. Methods of chiral synthesis of such compounds are provided. ... Celgene Corporation

10/05/17 / #20170281623

Solid forms of an epidermal growth factor receptor kinase inhibitor

The present invention provides a solid form and composites thereof, which are useful as an inhibitor of egfr kinases and which exhibit desirable characteristics for the same.. . ... Celgene Corporation

10/05/17 / #20170281597

Methods of using (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione

Stereomerically pure (+)-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, substantially free of its (−) isomer, and prodrugs, metabolites, polymorphs, salts, solvates, hydrates, and clathrates thereof are discussed. Also discussed are methods of using and pharmaceutical compositions comprising the (+) enantiomer of 2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione are disclosed. ... Celgene Corporation

09/28/17 / #20170275266

Histone demethylase inhibitors

Provided herein are substituted pyrazolylpyridine, pyrazolylpyridazine, and pyrazolylpyrimidine derivative compounds and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful for inhibition histone demethylase. ... Celgene Corporation

09/21/17 / #20170267658

Processes for the preparation of isotopologues of 3-(4-((4-(morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione and pharmaceutically acceptable salts thereof

Provided are processes for the preparation of isotopologues of 3-(4-((4-(morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione, or a pharmaceutically acceptable salt thereof.. . ... Celgene Corporation

09/14/17 / #20170258803

Salts and solid forms of (s)-3-(4-((4-(morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione and compositions comprising and methods of using the same

Salts and solid forms of 3-(4-((4-(morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione, or a stereoisomer thereof, are disclosed. Compositions comprising and methods of using the salts and solid forms are also disclosed.. ... Celgene Corporation

09/14/17 / #20170258778

Solid forms comprising 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione and a coformer, compositions and methods of use thereof

Provided herein are solid forms comprising (a) 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione and (b) a coformer. Pharmaceutical compositions comprising the solid forms (e.g., cocrystals) and methods for treating, preventing and managing various disorders are also disclosed.. ... Celgene Corporation

08/31/17 / #20170247695

Isotopologues of smad7 antisense oligonucleotides

This disclosure relates generally to deuterated isotopologues of smad7 antisense oligonucleotides, pharmaceutical compositions containing the same, and methods of using the same.. . ... Celgene Corporation

08/24/17 / #20170242014

Methods for treating solid tumors and the use of biomarkers as a predictor of clinical sensitivity to immunomodulatory therapies

A method of identifying a subject having a solid tumor who is likely to be responsive to a treatment compound, comprising: administering the treatment compound to a subject having the solid tumor; obtaining a sample from the subject; determining the level of a biomarker in the sample from the subject, and diagnosing the subject as being likely to be responsive to the treatment compound if the level of the biomarker in the sample of the subject changes as compared to a reference level of the biomarker.. . ... Celgene Corporation

08/24/17 / #20170240546

Histone demethylase inhibitors

The present invention relates generally to compositions and methods for treating cancer and neoplastic disease. Provided herein are substituted pyrido[3,4-d]pyrimidin-4-one derivative compounds and pharmaceutical compositions comprising said compounds. ... Celgene Corporation

08/24/17 / #20170240529

Histone demethylase inhibitors

The present invention relates generally to compositions and methods for treating cancer and neoplastic diseases. Provided herein are substituted imidazole-pyridine derivative compounds and pharmaceutical compositions comprising said compounds. ... Celgene Corporation

08/24/17 / #20170240332

Nested packaging for pharmaceutical products, and methods of distributing pharmaceutical products using same

A pharmaceutical product can be distributed to respective patients in a plurality of jurisdictions. First and second jurisdictions can have different labeling requirements than each other. ... Celgene Corporation

08/17/17 / #20170233736

Methods for dosing and monitoring smad7 antisense oligonucleotide treatment using biomarker levels

Methods of treating ibd in a subject using an anti-smad7 therapy, such as a smad7 antisense oligonucleotide, to reduce ccl20, il8, or tnfα levels are disclosed. Methods of treating and managing ibd in a subject using an anti-smad7 therapy, such as a smad7 antisense oligonucleotide, based on ccl20, il8, or tnfα levels are also disclosed. ... Celgene Corporation

08/17/17 / #20170232030

Combination therapy for treating cancer

The disclosure relates to combinations comprising inhibitors of human histone methyltransferase dot1l and one or more therapeutic agents, particularly anticancer agents, and methods of combination therapy for administering to subjects in need thereof for the treatment of cancer.. . ... Celgene Corporation

08/10/17 / #20170226083

Forms and compositions of an erk inhibitor

The present invention provides compounds, compositions thereof, and methods of using the same for the inhibition of one or both of erk1 and erk2.. . ... Celgene Corporation

08/03/17 / #20170218353

Ligand-directed covalent modification of protein

. . The present invention relates to enzyme inhibitors. More specifically, the present invention relates to ligand-directed covalent modification of proteins; method of designing same; pharmaceutical formulation of same; and method of use.. ... Celgene Corporation

08/03/17 / #20170217904

Salts of an epidermal growth factor receptor kinase inhibitor

The present invention provides a salt form and compositions thereof, which are useful as an inhibitor of egfr kinases and which exhibits desirable characteristics for the same.. . ... Celgene Corporation

08/03/17 / #20170216432

Methods of treating a disease or disorder associated with bruton's tyrosine kinase

The present invention provides methods of treating, stabilizing or lessening the severity or progression of a disease or disorder associated with btk.. . ... Celgene Corporation

07/27/17 / #20170210729

Erk inhibitors and uses thereof

The present invention provides compounds, compositions thereof, and methods of using the same.. . ... Celgene Corporation

07/13/17 / #20170199193

Methods for treating cancer and the use of biomarkers as a predictor of clinical sensitivity to therapies

A method of identifying a subject having cancer who is likely to be responsive to a treatment compound, comprising administering the treatment compound to the subject having the cancer; obtaining a sample from the subject; determining the level of a biomarker in the sample from the subject; and diagnosing the subject as being likely to be responsive to the treatment compound if the level of the biomarker in the sample of the subject changes as compared to a reference level of the biomarker; wherein the treatment compound is a compound of formula i:. . ... Celgene Corporation

07/13/17 / #20170197934

Solid forms of 2-(4-chlorophenyl)-n-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-2,2-difluoroacetamide, and their pharmaceutical compositions and uses

Solid forms comprising 2-(4-chlorophenyl)-n-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-2,2-difluoroacetamide, compositions comprising the solid forms, methods of making the solid forms and methods of their uses are disclosed.. . ... Celgene Corporation

07/13/17 / #20170197933

Antiproliferative compounds, and their pharmaceutical compositions and uses

Compounds of formula a-i and b-i, compositions comprising the compounds, methods of making the compounds and methods of their uses are disclosed.. . ... Celgene Corporation

07/13/17 / #20170196847

Formulations of 2-(4-chlorophenyl)-n-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-2,2-difluoroacetamide

Provided herein are lyophilized formulations of 2-(4-chlorophenyl)-n-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-2,2-difluoroacetamide or a stereoisomer or mixture of stereoisomers, pharmaceutically acceptable salt, tautomer, prodrug, solvate, hydrate, co-crystal, clathrate, or polymorph thereof. Methods of using the formulations and dosage forms for treating, managing, and/or preventing cancer are also provided herein.. ... Celgene Corporation

06/29/17 / #20170183325

Histone demethylase inhibitors

The present disclosure relates generally to compositions and methods for treating cancer and neoplastic disease. Provided herein are substituted pyridine derivative compounds, and compositions (including pharmaceutical compositions) that include these compounds. ... Celgene Corporation

06/29/17 / #20170182025

Bromodomain and extra-terminal protein inhibitor combination therapy

The present disclosure relates generally to compositions and methods of treating cancers, such as glioblastoma and non-hodgkin's lymphomas, or other cancers in which the subject suffers from an advanced solid tumor, comprising the administration of a bromodomain and extra-terminal protein (bet) inhibitor and at least one chemotherapeutic agent, which does not inhibit bet directly. The bet inhibitor/chemotherapeutic agent combination therapy can yield synergistic effects, thereby increasing the effectiveness of the cancer treatment as compared to the administration of either the bet inhibitor or the chemotherapeutic agent alone.. ... Celgene Corporation

06/22/17 / #20170174691

Protein kinase conjugates and inhibitors

The invention relates to protein conjugates that contain a protein kinase containing a cysteine residue in the atp binding site and an inhibitor that is covalently and irreversibly bonded to said cysteine residue, such that the activity of the protein kinase is irreversibly inhibited. The invention also relates to compounds that irreversibly inhibit protein kinases.. ... Celgene Corporation

06/22/17 / #20170174656

Histone demethylase inhibitors

The present invention relates generally to compositions and methods for treating cancer and neoplastic disease. Provided herein are substituted 3-aminopyridine derivative compounds, substituted 3-aminopyridazine derivative compounds, and pharmaceutical compositions comprising said compounds. ... Celgene Corporation

06/22/17 / #20170173029

3-(4-((4-(morpholinomethyl-benzyl)oxy)-1 -oxoisoindolin-2-yl)piperidine-2,6-dione for the treatment of systemic lupus erythematosus

Provided herein are methods of using compounds and compositions for treating, managing, and/or preventing systemic lupus erythematosus (sle). Pharmaceutical compositions and dosing regimens for use in the methods are also provided herein.. ... Celgene Corporation

06/22/17 / #20170173011

Methods of treating a bruton's tyrosine kinase disease or disorder

The present invention provides methods of treating, stabilizing or lessening the severity or progression of a disease or disorder associated with bruton's tyrosine kinase (btk) tec and interleukin-2-inducible t-cell kinase (itk).. . ... Celgene Corporation

06/15/17 / #20170165266

Use of 3-(5-amino-2-methyl-4-oxoquinazolin-3(4h)-yl)piperidine-2,6-dione in treatment of immune-related and inflammatory diseases

Provided herein are methods of using compounds and compositions for modulating lymphocytic activity, including activity of b cells and/or t cells, in immune-related diseases or inflammatory diseases. Pharmaceutical compositions and dosing regimens for use in the methods are also provided herein.. ... Celgene Corporation

06/15/17 / #20170165236

Selective sphingosine 1 phosphate receptor modulators and combination therapy therewith

Compounds that selectively modulate the sphingosine 1 phosphate receptor are provided, including compounds which modulate subtype 1 of the s1p receptor, and methods of their therapeutic and/or prophylactic use in combination with at least one other medicament adapted for treatment of a malcondition for which activation of s1p1 is medically indicated, such as multiple sclerosis.. . ... Celgene Corporation

06/08/17 / #20170158709

Bromodomain inhibitors

The present invention relates to substituted heterocyclic derivative compounds, compositions comprising said compounds, and the use of said compounds and compositions for epigenetic regulation by inhibition of bromodomain-mediated recognition of acetyl lysine regions of proteins, such as histones. Said compositions and methods are useful for the treatment of cancer and neoplastic disease.. ... Celgene Corporation

06/08/17 / #20170158685

Histone demethylase inhibitors

The present disclosure relates generally to compositions and methods for treating cancer and neoplastic disease. Provided herein are substituted pyridine derivative compounds and pharmaceutical compositions comprising said compounds. ... Celgene Corporation

06/08/17 / #20170158681

Histone demethylase inhibitors

The present invention relates generally to compositions and methods for treating cancer and neoplastic disease. Provided herein are substituted amidopyridine or amidopyridazine derivative compounds and pharmaceutical compositions comprising said compounds. ... Celgene Corporation

06/08/17 / #20170158664

Histone demethylase inhibitors

Provided herein are substituted pyrazolylpyridine, pyrazolylpyridazine, and pyrazolylpyrimidine derivative compounds and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful for inhibition histone demethylase. ... Celgene Corporation

06/08/17 / #20170157123

Cycling therapy using 3-(5-amino-2-methyl-4-oxo-4h-quinazolin-3-yl)-piperidine-2,6-dione

Provided herein are methods of treating, preventing and/or managing cancer, including lymphoma, which comprise administering to a patient 3-(5-amino-2-methyl-4-oxo-4h-quinazolin-3-yl)-piperidine-2,6-dione, or an enantiomer or a mixture of enantiomers thereof, or a pharmaceutically acceptable salt, solvate, hydrate, co-crystal, clathrate, or polymorph thereof in a cyclic therapy regimen.. . ... Celgene Corporation

06/08/17 / #20170157103

Methods of treating diffuse large b-cell lymphoma using 3-(4-amino-1-oxoisoindolin-2-yl)piperidine-2,6-dione

Provided herein are methods of treating, preventing and/or managing diffuse large b-cell lymphoma (dlbcl), which comprise administering to a patient 3-(4-amino-1-oxoisoindolin-2-yl)piperidine-2,6-dione, or an enantiomer or a mixture of enantiomers thereof, or a pharmaceutically acceptable salt, solvate, hydrate, co-crystal, clathrate, or polymorph thereof.. . ... Celgene Corporation

05/18/17 / #20170137463

Hcv protease inhibitors and uses thereof

The present invention provides compounds, pharmaceutically acceptable compositions thereof, and methods of using the same.. . ... Celgene Corporation

05/18/17 / #20170137406

Erk inhibitors and uses thereof

The present invention provides compounds, compositions thereof, and methods of using the same.. . ... Celgene Corporation

05/18/17 / #20170137402

Inhibitors of lysine specific demethylase-1

The present invention relates generally to compositions and methods for treating cancer and neoplastic disease. Provided herein are substituted heterocyclic derivative compounds and pharmaceutical compositions comprising said compounds. ... Celgene Corporation

05/11/17 / #20170129882

Inhibitors of lysine specific demethylase-1

The present invention relates generally to compositions and methods for treating cancer and neoplastic disease. Provided herein are substituted heterocyclic derivative compounds and pharmaceutical compositions comprising said compounds. ... Celgene Corporation

05/11/17 / #20170129873

6-, 7-, or 8-substituted quinazolinone derivatives and compositions comprising and methods of using the same

Provided are quinazolinone compounds, and pharmaceutically acceptable salts, solvates, clathrates, stereoisomers, and prodrugs thereof. Methods of use, and pharmaceutical compositions of these compounds are disclosed.. ... Celgene Corporation

05/11/17 / #20170129871

Compositions comprising an inhibitor of lysine specific demethylase-1

Described herein are amorphous and crystalline forms of pharmaceutically acceptable salts of the lysine specific demethylase-1 inhibitor 4-[2-(4-amino-piperidin-1-yl)-5-(3-fluoro-4-methoxy-phenyl)-1-methyl-6-oxo-1,6-dihydro-pyrimidin-4-yl]-2-fluorobenzonitrile. Also described are pharmaceutical compositions suitable for administration to a mammal that include the lysine specific demethylase-1 inhibitor, and methods of using the lysine specific demethylase-1 inhibitor for treating diseases or conditions that are associated with lysine specific demethylase-1 activity.. ... Celgene Corporation

05/11/17 / #20170129852

Processes for the preparation of (s)-1-(3-ethoxy-4-methoxyphenyl)-2-methanesulfonylethylamine

Provided herein are new processes for the preparation of aminosulfone intermediates for the synthesis of 2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, which is useful for preventing or treating diseases or conditions related to an abnormally high level or activity of tnf-α. Further provided herein are processes for the commercial production of (s)-1-(3-ethoxy-4-methoxyphenyl)-2-methanesulfonylethylamine.. ... Celgene Corporation

05/11/17 / #20170128448

Combination therapy for cancer

Provided herein are methods of treating, preventing and/or managing lymphomas and leukemias by administering to a patient compound a (3-(5-amino-2-methyl-4-oxo-4h-quinazolin-3-yl)-piperidine-2,6-dione), or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof, in combination with an anti-cd20 antibody or ibrutinib, or a pharmaceutically acceptable salt or solvate thereof. . ... Celgene Corporation

05/04/17 / #20170121305

Polymorphic forms of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione

Polymorphic forms of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione are disclosed. Compositions comprising the polymorphic forms, methods of making the polymorphic forms and methods of their use are also disclosed.. ... Celgene Corporation

05/04/17 / #20170121304

Polymorphic forms of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione

Polymorphic forms of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione are disclosed. Compositions comprising the polymorphic forms, methods of making the polymorphic forms and methods of their use are also disclosed.. ... Celgene Corporation

05/04/17 / #20170121303

Polymorphic forms of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione

Polymorphic forms of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione are disclosed. Compositions comprising the polymorphic forms, methods of making the polymorphic forms and methods of their use are also disclosed.. ... Celgene Corporation

04/27/17 / #20170114073

Mk2 inhibitors and uses thereof

The present invention provides compounds, compositions thereof, and methods of using the same.. . ... Celgene Corporation

04/27/17 / #20170114055

Histone demethylase inhibitors

The present disclosure relates generally to compositions and methods for treating cancer and neoplastic disease. Provided herein are substituted pyridine derivative compounds and pharmaceutical compositions comprising said compounds. ... Celgene Corporation

04/27/17 / #20170114024

Inhibitors of lysine specific demethylase-1

The present invention relates generally to compositions and methods for treating cancer and neoplastic disease. Provided herein are substituted heterocyclic derivative compounds and pharmaceutical compositions comprising said compounds. ... Celgene Corporation

04/27/17 / #20170112819

Methods for treating multiple myeloma with 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione after stem cell transplantation

Methods of treating, preventing and/or managing cancer as well as and diseases and disorder associated with, or characterized by, undesired angiogenesis are disclosed. Specific methods encompass the administration of an immunomodulatory compound alone or in combination with a second active ingredient. ... Celgene Corporation

04/13/17 / #20170100397

Heteroaryl compounds and uses thereof

The present invention provides compounds, pharmaceutically acceptable compositions thereof, and methods of using the same.. . ... Celgene Corporation

04/06/17 / #20170097360

Methods for treating inflammatory and other diseases and the use of biomarkers as predictors of clinical sensitivity to treatment with apremilast

Provided herein are methods for predicting the clinical sensitivity of an inflammatory disease (e.g., ankylosing spondylitis) and a subject's response to treatment with apremilast using the level of a biomarker (e.g., mcp1). Also provided herein are methods for treating an inflammatory disease.. ... Celgene Corporation

04/06/17 / #20170095475

Heteroaryl compounds and uses thereof

The present invention provides compounds, pharmaceutically acceptable compositions thereof, and methods of using the same.. . ... Celgene Corporation

04/06/17 / #20170095464

Methods using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for treatment of certain leukemias

Methods of treating, preventing or managing leukemias are disclosed. The methods encompass the administration of an immunomodulatory compound of the invention known as revlimid® or lenalidomide. ... Celgene Corporation

03/30/17 / #20170088901

Methods for treating diffuse large b-cell lymphoma and the use of biomarkers as a predictor of responsiveness to drugs

In one aspect, provided herein are methods for predicting the responsiveness of dlbcl patients to treatment with lenolidomide or compound a; or a stereoisomer thereof; or a pharmaceutically acceptable salt, solvate, hydrate, co-crystal, clathrate thereof; or a polymorph thereof utilizing biomarkers or classfiers that correlate with responsiveness to one of these drugs. In another aspect, provided herein are methods for treating a dlbcl patient determined to be responsive to treatment with lenolidomide or compound a; or a stereoisomer thereof; or a pharmaceutically acceptable salt, solvate, hydrate, co-crystal, clathrate thereof; or a polymorph thereof utilizing biomarkers or classifiers (or output thereof) that correlate with responsiveness to one of these drugs.. ... Celgene Corporation

03/30/17 / #20170088618

Pd-1 binding proteins and methods of use thereof

Provided herein are compositions, methods and uses involving antibodies that specifically bind to programmed death-1 (pd-1) and modulate the expression and/or activity of pd-1.. . ... Celgene Corporation

03/30/17 / #20170088538

Isoindoline compounds and methods of their use

Provided herein are isoindoline compounds, pharmaceutical compositions comprising one or more of such compounds, and methods of their use for treating, preventing, or managing various diseases.. . ... Celgene Corporation

03/30/17 / #20170087129

Compositions and methods for the treatment of atherosclerotic cardiovascular diseases with pde4 modulators

Provided herein are methods of treating, preventing or managing atherosclerosis by administering a pde4 modulator. Pharmaceutical compositions, dosage forms, and kits suitable for use in methods are also provided.. ... Celgene Corporation

03/09/17 / #20170066739

Histone demethylase inhibitors

The present invention relates generally to compositions and methods for treating cancer and neoplastic diseases. Provided herein are substituted imidazole-pyridine derivative compounds and pharmaceutical compositions comprising said compounds. ... Celgene Corporation

03/02/17 / #20170056323

Formulations of 3-(5-amino-2-methyl-4-oxo-4h-quinazolin-3-yl)-piperidine-2,6-dione

Pharmaceutical compositions and single unit dosage forms of compound a (3-(5-amino-2-methyl-4-oxo-4h-quinazolin-3-yl)-piperidine-2,6-dione), or an enantiomer or a mixture of enantiomers thereof, a pharmaceutically acceptable salt, solvate, hydrate, co-crystal, clathrate, or polymorph thereof, are provided herein. Also provided are methods of treating, managing, or preventing cancer using the dosage forms described herein.. ... Celgene Corporation

02/23/17 / #20170050968

Bromodomain inhibitor

The present invention relates to substituted heterocyclic derivative compounds, compositions comprising said compounds, and the use of said compounds and compositions for epigenetic regulation by inhibition of bromodomain-mediated recognition of acetyl lysine regions of proteins, such as histones. Said compositions and methods are useful for the treatment of cancer and neoplastic disease.. ... Celgene Corporation

02/09/17 / #20170038387

Methods for treating chronic lymphocytic leukemia and the use of biomarkers as a predictor of clinical sensitivity to immunomodulatory therapies

A method of identifying a subject having chronic lymphocytic leukemia (cll) who is likely to be responsive to a treatment compound, comprising obtaining a first sample and a second sample from the subject having cll; administering 3-(5-amino-2-methyl-4-oxo-4h-quinazolin-3-yl)-piperidine-2,6-dione (compound a) to the first sample and administering lenalidomide to the second sample; determining the level of a biomarker in the first sample and determining the level of the biomarker in the second sample; and diagnosing the subject as being likely to be responsive to the treatment compound if the level of the biomarker in the first sample is different from the level of the biomarker in the second sample.. . ... Celgene Corporation

02/02/17 / #20170027937

Heterocyclic compounds and uses thereof

The present invention provides compounds, pharmaceutically acceptable compositions thereof, and methods of using the same.. . ... Celgene Corporation

02/02/17 / #20170027923

Methods using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for treatment of mantle cell lymphomas

Methods of treating, preventing or managing mantle cell lymphomas are disclosed. The methods encompass the administration of an immunomodulatory compound of the invention known as revlimid® or lenalidomide. ... Celgene Corporation

01/12/17 / #20170007665

Romidepsin formulations and uses thereof

Provided herein are liquid concentrate formulations of romidepsin. Also provided are methods for producing these formulations and uses thereof. ... Celgene Corporation

01/12/17 / #20170007645

Methods of using an activator of cereblon for neural cell expansion and the treatment of central nervous system disorders

Provided herein, for example, are methods generally relating to the expansion and/or regeneration of central nervous system (cns) cells, such as nerve cells, astrocytes and oligodendrocytes, using an activator of cereblon (crbn), such as an inhibitor of a crbn substrate or downstream protein. Also provided herein, for example, are methods related to the expansion of neural stem cells, neural progenitor cells, or neural precursor cells and/or differentiation of these cells into cns cells using a brd7 antagonist, ikaros antagonist, or crbn activator. ... Celgene Corporation

01/12/17 / #20170007590

Antiproliferative compounds and methods of use thereof

Compounds of formula i for treating, preventing or managing cancer are disclosed. Also disclosed are methods of treating, preventing or managing cancer, such as leukemia, comprising administering the compounds. ... Celgene Corporation

01/05/17 / #20170000845

Romidepsin formulations and uses thereof

Provided herein are liquid concentrate formulations of romidepsin. Also provided are methods for producing these formulations and uses thereof. ... Celgene Corporation








ARCHIVE: New 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009



###

This listing is an abstract for educational and research purposes is only meant as a recent sample of applications filed, not a comprehensive history. Freshpatents.com is not affiliated or associated with Celgene Corporation in any way and there may be associated servicemarks. This data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Celgene Corporation with additional patents listed. Browse our Agent directory for other possible listings. Page by FreshPatents.com

###